RxDoctor Payments Data

Norbert Brehm, MD

Urology · Corpus Christi, TXNPI 1699761213

Payments from drug & device makers

$2,624in general payments, 2019–2025

Across 120 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$811
  • AbbVie$522
  • Teleflex LLC$400
  • Urovant Sciences Inc$113
  • Agiliti Surgical, Inc.$97
  • Myovant Sciences Inc.$86
  • plus $594 from 15 others

What the payments were for

  • Travel & lodging$32612%
  • Food & beverage$2,01477%
  • Education$28511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,624 in reported general payments places this provider in the 40th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$576,922
Medicare patients
1,351
Services billed
31,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron247$137,333
GemtesaVibegron88$65,301
NitrofurantoinNitrofurantoin Macrocrystal178$10,084
Mirabegron ErMirabegron13$7,168
Finasteride507$6,694
Solifenacin Succinate175$6,625
Tamsulosin Hcl533$6,477
Cephalexin159$3,833
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst124$2,944
CefuroximeCefuroxime Axetil259$2,848
Oxybutynin Chloride153$2,574
Trimethoprim26$2,177
Doxycycline Hyclate151$2,134
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip47$1,067
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav76$647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$811$137,333247 claims
Sumitomo Pharma America, Inc.Gemtesa$49$65,30188 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 878 urology providers in Texas.

Other urology in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →